Silk Road Medical - SILK Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Silk Road Medical in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SILK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SILK, but not buy additional shares or sell existing shares.
View SILK analyst ratings or view top-rated stocks.

5 brokers have issued 12-month price targets for Silk Road Medical's stock. Their SILK share price forecasts range from $43.00 to $70.00. On average, they expect the company's share price to reach $53.57 in the next year. This suggests a possible upside of 36.9% from the stock's current price.
View analysts price targets for SILK or view top-rated stocks among Wall Street analysts.

Silk Road Medical's stock was trading at $52.85 at the beginning of 2023. Since then, SILK stock has decreased by 26.0% and is now trading at $39.13.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our SILK earnings forecast.

Silk Road Medical, Inc (NASDAQ:SILK) issued its earnings results on Tuesday, February, 28th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.03. The business earned $40.07 million during the quarter, compared to the consensus estimate of $37.35 million. Silk Road Medical had a negative trailing twelve-month return on equity of 63.30% and a negative net margin of 39.81%. Silk Road Medical's revenue was up 41.8% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.42) EPS.

ETFs with the largest weight of Silk Road Medical (NASDAQ:SILK) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), American CenturyFocused Dynamic Growth ETF (FDG), First Trust Small Cap Growth AlphaDEX Fund (FYC), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Future Gen 200 ETF (QQQS), Global X Aging Population ETF (AGNG), IQ Chaikin U.S. Small Cap ETF (CSML) and Vanguard Health Care ETF (VHT).

Silk Road Medical updated its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $176.00 million-$184.00 million, compared to the consensus revenue estimate of $172.70 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Silk Road Medical investors own include Raytheon Technologies (RTX), Procter & Gamble (PG), Abbott Laboratories (ABT), Cisco Systems (CSCO), Pfizer (PFE), Edwards Lifesciences (EW), Honeywell International (HON), CSX (CSX), Thermo Fisher Scientific (TMO) and Alibaba Group (BABA).

(SILK) raised $75 million in an initial public offering on Thursday, April 4th 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and BMO Capital Markets and Stifel were co-managers.

Silk Road Medical trades on the NASDAQ under the ticker symbol "SILK."

Shares of SILK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SILK stock can currently be purchased for approximately $39.13.

Silk Road Medical (NASDAQ:SILK) has a market capitalization of $1.50 billion and generates $138.64 million in revenue each year. The company earns $-55,010,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis.

The company employs 352 workers across the globe.

Silk Road Medical's mailing address is 1213 INNSBRUCK DR., SUNNYVALE CA, 94089. The official website for the company is www.silkroadmed.com. The company can be reached via phone at (408) 720-9002, via email at investors@silkroadmed.com, or via fax at 408-720-9013.